{"preliminary_commentary":{"by_channel":{"x_thread":3,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT05029882","nct_id":"NCT05029882","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05029882. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants with advanced solid tumors will receive escalating doses of ABBV-400.","label":"Part 1 (Monotherapy Dose Escalation)","type":"EXPERIMENTAL"},{"description":"Participants with non-squamous wtEGFR NSCLC will receive ABBV-400 at the Recommended Phase 2 dose (RP2D).","label":"Part 2i (wtEGFR Non-Small Cell Lung Cancer [NSCLC])","type":"EXPERIMENTAL"},{"description":"Participants with non-Squamous mutEGFR NSCLC will receive ABBV-400 at RP2D.","label":"Part 2ii (mutEGFR NSCLC)","type":"EXPERIMENTAL"},{"description":"Participants with squamous NSCLC will receive ABBV-400 at RP2D.","label":"Part 2iii (Squamous NSCLC)","type":"EXPERIMENTAL"},{"description":"Participants with gastroesophageal adenocarcinoma will receive ABBV-400 at the RP2D.","label":"Part 3 (Gastroesophageal Adenocarcinoma/Gastroesophagel Junct","type":"EXPERIMENTAL"},{"description":"Participants with Colorectal Cancer (CRC) will receive ABBV-400 at the RP2D and various dose levels for dose optimization.","label":"Part 4 (Colorectal Cancer)","type":"EXPERIMENTAL"},{"description":"Participants with mesenchymal-epithelial transition proto-oncogene (MET) amplification will receive ABBV-400 at the RP2D and various dose levels for dose optimization.","label":"Part 5 (MET Amplification)","type":"EXPERIMENTAL"},{"description":"Participants with MET mutation will receive ABBV-400 at the RP2D and various dose levels for dose optimization.","label":"Part 6 (MET Mutation)","type":"EXPERIMENTAL"},{"description":"Participants with CRC will receive escalating doses of ABBV-400 in combination with bevacizumab.","label":"Part 7a (Combination Dose Escalation)","type":"EXPERIMENTAL"},{"description":"Participants with CRC will receive the low dose determined in the dose escalation arm (Part 7a) of ABBV-400 in combination with bevacizumab.","label":"Part 7bi (Combination Dose Optimization Low Dose)","type":"EXPERIMENTAL"},{"description":"Participants with CRC will receive the high dose determined in the dose escalation arm (Part 7a) of ABBV-400 in combination with bevacizumab.","label":"Part 7bii (Combination Dose Optimization High Dose)","type":"EXPERIMENTAL"},{"description":"Participants with CRC will receive trifluridine/tipiracil (TAS-102) in combination with bevacizumab.","label":"Part 7biii (Combination Comparator)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-11","type":"ESTIMATED"},"conditions":["Non-Small Cell Lung Cancer","Advanced Solid Tumors","Gastroesophageal Adenocarcinoma","Colorectal Cancer"],"enrollment":{"count":520,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"ABBV-400","otherNames":[],"type":"DRUG"},{"name":"Trifluridine/Tipiracil","otherNames":["TAS-102"],"type":"DRUG"},{"name":"Bevacizumab","otherNames":[],"type":"DRUG"}],"last_update":"2025-10-29","lead_sponsor":"AbbVie","official_title":"A Phase 1 First in Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-400 as Monotherapy and in Combination With Bevacizumab in Adult Subjects With Advanced Solid Tumors","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2027-11","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Objective Response Rate (ORR)","timeFrame":"Up to 48 Months"}],"references":[{"citation":"Sharma MR, Powderly J, Kuboki Y, Strickler JH, Perets R, Cohen JE, Raimbourg J, Nakajima TE, Yamamoto N, Cruz-Correa M, O'Neil B, Ghiringhelli F, Raghav K, Cecchini M, Bar J, Hunter Z, Burns M, Blaney M, Morrison-Thiele G, Aristide MN, Freise KJ, Li R, Li M, Vasilopoulos A, Biesdorf C, Sommerhalder D. Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors. J Clin Oncol. 2026 Jul 10;44(20):1876-1888. doi: 10.1200/JCO-25-01525. Epub 2026 May 1.","pmid":"42066233","type":"DERIVED"}],"start_date":{"date":"2021-10-13","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab","url":"https://clinicaltrials.gov/study/NCT05029882"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05029882"}